Also, genetic studies demonstrated that specific PCSK9 variants might increase the risk for the development of diabetes mellitus type 2 (T2D) [10], however this finding could not be evidently verified in randomized controlled trials (RCTs) when PCSK9 inhibitors were exogenously administered [11]. The gene discussed is PCSK9; the disease is diabetes mellitus.